IBEX Ltd Chief Legal Officer Christina Alice Trofimuk-O’Connor earned 3,228 performance-based stock units on September 30, 2026; the units converted to Common shares after certification of performance goals for the two-year period ending June 30, 2026. The issuer withheld 1,159 shares to satisfy her tax liability upon vesting. The footnote says the withholding was not discretionary and she did not sell shares to satisfy the liability; no Rule 10b5-1 plan is reported.
IBEX Ltd Chief People Officer Paul Joseph Inson acquired 2,348 common shares on September 30, 2026, when earned performance-based stock units converted to common shares. The units were earned upon certification of performance goals for the two-year period ending June 30, 2026.
The issuer withheld 1,028 common shares to satisfy Inson’s tax liability upon vesting. The withholding was not discretionary, and no shares were sold to satisfy the liability. The reported $43.26 per-share price was the issuer’s closing price on September 30, 2026.
IBEX Ltd Chief Financial Officer Taylor C. Greenwald earned 4,196 performance-based stock units (PSUs) on September 30, 2026, after certification of performance goals for the two-year period ending June 30, 2026; the PSUs converted to Common shares. IBEX Ltd withheld 1,843 shares for Greenwald’s tax liability upon vesting; the footnote says this was not discretionary and no shares were sold by the reporting person. The reported $43.26 per share was the closing price of IBEX Ltd Common shares on September 30, 2026.
IBEX Ltd Chief Executive Officer Robert Thomas Dechant sold 5,000 common shares on September 25, 2026, at a weighted average price of $45.0191 per share. The sales were made under his 10b5-1 Plan dated November 18, 2025, and execution prices ranged from $45.00 to $45.060. After the sale, Dechant directly held 257,011 shares.
IBEX Ltd (IBEX) director Daniella Ballou-Aares gave notice of a proposed sale of 1,500 common shares through Goldman Sachs & Co. LLC, with an aggregate market value of $60,436.50 and an approximate sale date of September 15, 2026. The shares were acquired from the issuer in a restricted stock grant on December 28, 2018. The amendment corrects the broker’s name and address. Lisa Lenstrohm signed as attorney-in-fact for Daniella Ballou-Aares.
IBEX Ltd officer and director Robert Thomas Dechant reports 5,000 common shares for sale, with an aggregate market value of $225,095.00 and an approximate sale date of September 25, 2026. RBC Capital Markets LLC is listed as the broker, and NASDAQ is listed as the exchange. Remarks state that the sale is pursuant to a Rule 10b5-1 plan established November 18, 2025.
IBEX Ltd Chief AI & Digital Officer Darwal Michael Joseph had 270 common shares withheld by the issuer on September 15, 2026, to satisfy tax liability upon vesting of RSUs. The reported per-share price was the issuer’s closing price that day: $40.28. The withholding was not discretionary, and Joseph sold no shares; his direct holdings after the transaction were 40,474 shares. No Rule 10b5-1 plan is reported.
IBEX Ltd Chief Financial Officer Taylor C. Greenwald had 3,293 common shares withheld for tax purposes upon vesting of a restricted stock grant on September 18, 2026. The reported price was the $40.20 closing price. Direct holdings following the transaction were 60,435 common shares; no Rule 10b5-1 plan is reported.
IBEX Ltd received a Rule 144 notice for a proposed sale of common shares by director Daniella Ballou-Aares. The filing covers up to 1,500 shares of common stock, originally acquired through a restricted stock grant on December 28, 2018, to be sold through Goldman Sachs Custody Solutions on Nasdaq.
IBEX Ltd (IBEX) director Daniella Ballou-Aares reported selling 1,500 Common Shares on September 15, 2026 in an open-market or private transaction at a price of $40.291 per share. After this transaction, she directly holds 10,395 Common Shares of IBEX. No Rule 10b5-1 trading plan is reported for this sale.